Norris Medicines Ltd

Norris Medicines Q2 2025: Revenue Up, Losses Widen 📊💊

- Revenue: ₹200.04L in Q2 (Sep 2025) vs ₹145.66L in Q1 (Jun 2025) – 37% quarterly growth

- Year-over-year: Q2 revenue up from ₹126.84L in Sep 2024

- Losses: Q2 loss at ₹-71.82L vs ₹-31.04L in Q1 and ₹-36.11L in Q2 2024

- Half-year loss: ₹-102.86L (Sep 2025) vs ₹-72.73L (Sep 2024)

- Assets: ₹1,349L total (₹723L non-current, ₹626L current)

- Equity: Negative ₹-1,589L (₹993L share capital, ₹-2,582L other equity)

- Single-segment pharma business, no exceptional items reported